Atreca (NASDAQ: BCEL)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.780 | -0.650 | 0.1300 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Alzamend Neuro (NASDAQ:ALZN), HOOKIPA Pharma (NASDAQ:HOOK), Anixa Biosciences (NASDAQ:ANIX), Fortress Biotech (NASDAQ:FBIO) and Orchard Therapeutics (NASDAQ:ORTX).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Stifel on Friday, March 4, 2022. The analyst firm set a price target for 14.00 expecting BCEL to rise to within 12 months (a possible 533.48% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $2.21 last updated Today at July 6, 2022, 4:50 PM UTC.
There are no upcoming dividends for Atreca.
Atreca’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.